The April 20 report, the latest performance analysis commissioned by the Phoenix-based Flinn Foundation and presented by TEConomy Partners, shows record highs in bioscience jobs, wages, venture capital, National Institutes of Health research funding, and university research and development.Continue reading
Author Archive: AZBio
Aqualung Therapeutics Extends Global Reach With LeaderMed License Agreement
TUCSON, AZ / ACCESSWIRE / April 20, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the signing of a license agreement with the LeaderMed Health Group Limited (“LeaderMed”). The License Agreement provides LeaderMed with Asia-Pacific regional rights to further develop, manufacture, and commercialize the eNAMPT-neutralizing mAb, ALT-100 platform technology. The terms of the agreement have not been publicly disclosed but involve customary upfront fees, achievement milestones, and royalties that coincide with commercial sales.Continue reading
Flinn Foundation awards $1 million in grants to promote groundbreaking translational research
The first treatment for West Nile virus. A robotic device for children with cerebral palsy. A universal antivenom for snake bites. These goals emerge from three of the 10 translational research projects receiving funding from the Flinn Foundation in 2022 as part of a program to advance new products and services to improve patient care.Continue reading
AlphaLogix announces market release of AlphaFlo® canine allograft
PHOENIX, March 31, 2022 /PRNewswire/ — Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo®. Equus Innovations is also the manufacturer of the highly successful RenoVō® equine allograft, distributed by Equine Amnio Solutions, LLC (EAS).
New ASU center to create a better, more efficient blueprint for tech transfer
Global Center for Technology Transfer will focus on research, education
Flinn awards $5.5M grant to UArizona medical school in Phoenix to support translational research
The University of Arizona College of Medicine-Phoenix will receive $5.5 million over five years from the Flinn Foundation to support translational research in cardiovascular diseases, neurosciences, and serious mental illnesses.Continue reading
BIO Statement on CMS National Coverage Determination for Drugs Used to Treat Patients Suffering from Alzheimer’s Disease
On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease. In its official statement, the Biotechnology Innovation Organization (BIO) shares why the CMS Decision is an enormous setback for Alzheimer’s patients and a dangerous infringement on FDA’s Scientific Autonomy.
HTG Expands Features of Proprietary HTG EdgeSeq Technology
New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample
Phoenix to be Site of New UArizona Health Sciences Center Targeting Immunotherapies
The Center for Advanced Molecular and Immunological Therapies will provide staff, facilities, support and services to advance precision medicine.
Castle Biosciences to Acquire AltheaDx
Furthers mid- and long-term growth with strategic advance into pharmacogenomics and mental healthContinue reading